InflaRx Files Q1 2026 Financials with SEC via Form 6-K

InflaRx ( (IFRX) ) just unveiled an announcement.

InflaRx N.V. has filed a Form 6-K with the U.S. Securities and Exchange Commission for May 2026, incorporating its latest unaudited condensed consolidated financial statements and management’s discussion and analysis for the quarter ended March 31, 2026 into existing shelf and employee share plan registrations. The filing, signed on May 6, 2026 by CEO Niels Riedemann, updates U.S. investors on the company’s operating performance, cash flows and equity movements, underscoring continued transparency and maintaining the company’s eligibility to issue securities under its current SEC-registered programs.

The most recent analyst rating on (IFRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.

Spark’s Take on IFRX Stock

According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.

The score is held back primarily by very weak financial performance (minimal/declining revenue, persistent losses, and ongoing cash burn), partially offset by a relatively low-debt balance sheet. Technicals are supportive due to strong upward momentum, but overbought signals add near-term risk, while valuation is difficult to support given negative earnings and no dividend data.

To see Spark’s full report on IFRX stock, click here.

More about InflaRx

InflaRx N.V. is a Netherlands-incorporated biotechnology company with principal operations in Jena, Germany, developing anti-inflammatory therapies through its wholly owned subsidiaries in Germany and the United States. The group structures its activities via InflaRx GmbH and InflaRx Pharmaceuticals Inc., and reports its consolidated financial results in euros for global investors.

Average Trading Volume: 741,262

Technical Sentiment Signal: Buy

Current Market Cap: $154M

See more insights into IFRX stock on TipRanks’ Stock Analysis page.